Sidoti Csr Has Bearish Estimate for USNA Q1 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at Sidoti Csr decreased their Q1 2025 earnings estimates for USANA Health Sciences in a research report issued to clients and investors on Thursday, April 17th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will earn $0.70 per share for the quarter, down from their prior estimate of $0.71. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.67 EPS, FY2025 earnings at $2.59 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.39 EPS.

Several other research analysts have also issued reports on the stock. DA Davidson dropped their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $23.75 on Friday. The firm has a fifty day moving average of $28.44 and a 200-day moving average of $33.55. The stock has a market cap of $448.90 million, a price-to-earnings ratio of 8.39, a P/E/G ratio of 0.93 and a beta of 1.00. USANA Health Sciences has a 52-week low of $23.26 and a 52-week high of $49.78.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Insiders Place Their Bets

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,234 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $32.98, for a total value of $106,657.32. Following the transaction, the insider now owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jim Brown sold 5,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the sale, the chief executive officer now owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,920 shares of company stock valued at $500,285. 0.63% of the stock is currently owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently modified their holdings of the stock. R Squared Ltd acquired a new stake in shares of USANA Health Sciences in the fourth quarter valued at approximately $28,000. Versant Capital Management Inc lifted its holdings in USANA Health Sciences by 542.5% during the 1st quarter. Versant Capital Management Inc now owns 1,150 shares of the company’s stock worth $31,000 after buying an additional 971 shares in the last quarter. Parallel Advisors LLC boosted its position in USANA Health Sciences by 8,141.2% in the 1st quarter. Parallel Advisors LLC now owns 1,401 shares of the company’s stock valued at $38,000 after buying an additional 1,384 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of USANA Health Sciences in the 4th quarter valued at $83,000. Finally, Quantbot Technologies LP bought a new stake in shares of USANA Health Sciences during the fourth quarter worth $132,000. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.